This resource was retired on January 28, 2021 and is no longer updated. These data remain available to support research and development efforts. Pillbox's final image library is available at https://ftp.nlm.nih.gov/projects/pillbox/pillbox_production_images_full_202008.zip. For more information on Pillbox's retirement visit https://www.nlm.nih.gov/pubs/techbull/ja20/ja20_pillbox_discontinue.html.

Pillbox contains metadata for oral solid dosage form medications, derived from FDA drug labeling, including physical characteristics, active and inactive ingredients, National Drug Codes, information about firms marketing those products, selected information from RxNorm, and links to images provided by the National Library of Medicine.

This dataset is the master file of the Pillbox database of the US National Library of Medicine (NLM), which contains descriptive information on the existing medication pills in the market. Values supplied by the drug companies to FDA (Food and Drug Administration) as part of the Structured Product Labels are labeled "SPL". All other values are added by the National Library of Medicine’s (NLM) Pillbox or RxNorm datasets.

IntroductionDigital adherence technologies (DATs) can offer alternative approaches to support tuberculosis treatment medication adherence. Evidence on their feasibility and acceptability in high TB burden settings is limited. We conducted a cross-sectional survey among adults with drug-sensitive tuberculosis (DS-TB), participating in pragmatic cluster-randomized trials for the Adherence Support Coalition to End TB project in Ethiopia (PACTR202008776694999), the Philippines, South Africa and Tanzania (ISRCTN 17706019).MethodsFrom each country we selected 10 health facilities implementing the DAT intervention (smart pillbox or medication labels, with differentiated care support), ensuring inclusion of urban/rural and public/private facilities. Adults on DS-TB regimen using a DAT were randomly selected from each facility. Feasibility of the DATs was assessed using a standardized tool. Acceptability was measured using a 5-point Likert-scale, using the Capability, Opportunity, Motivation, Behavior (COM-B) model. Mean scores of Likert-scale responses within each COM-B category were estimated, adjusted for facility-level clustering. Data were summarized by country and DAT type.ResultsParticipants using either the pillbox (n = 210) or labels (n = 169) were surveyed. Among pillbox users, phone ownership (79%), use of pillbox reminders (87%) and taking treatment without the pillbox (22%) varied by country. Among label users, phone ownership (81%), paying extra to use the labels (8%) and taking treatment without using labels (41%) varied by country. Poor network, problems with phone charging and access, not having the pillbox and forgetting to send text were reasons for not using DATs. Overall, people with TB had a favorable impression of both DATs, with mean composite scores between 4·21 to 4·42 across COM-B categories. Some disclosure concerns were reported.ConclusionFrom client-perspective, pillboxes and medication labels with differentiated care support were feasible to implement and acceptable in variety of settings. However, implementation challenges related to network, phone access, stigma, additional costs to people with TB to use DATs need to be addressed.